ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

Source Summary

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new clinical and real-world data highlighting its integrase strand transfer inhibitor (INSTI)-focused portfolio, including long-acting (LA) medicines and pipeline momentum, to be presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from 26-31 July. VOGUE daily orals phase IIIb data will compare ViiV Healthcare’s